Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927918 | 0.99 | HTR7 (0.68) | HTR7HTR2CMTNR1AMTNR1BKDM4E | |
| SCHEMBL23956096 | 0.96 | HTR7 (0.72) | HTR7HTR2CMTNR1AMTNR1BHRH3 | |
| SCHEMBL23956095 | 0.93 | HTR7 (0.67) | HTR7HTR2CMTNR1AMTNR1BPRMT5 | |
| SCHEMBL23927917 | 0.87 | HTR7 (0.58) | HTR7HTR2CMTNR1AMTNR1BKDM4E | |
| SCHEMBL29780348 | 0.84 | HTR7 (0.49) | HTR7HRH3 | |
| SCHEMBL23927844 | 0.84 | HTR7 (0.49) | HTR7HRH3 | |
| SCHEMBL16705820 | 0.82 | HTR7 (0.63) | HTR7HTR2CPRMT5HTR2A | |
| SCHEMBL23927877 | 0.82 | HTR7 (0.50) | HTR7HRH3 | |
| SCHEMBL29780355 | 0.82 | HTR7 (0.50) | HTR7HRH3 | |
| SCHEMBL23956100 | 0.81 | HTR7 (0.52) | HTR7HTR2CMTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | HTR7 32/4885HTR2C 3/4885MTNR1A 61/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR7 32/4885HTR2C 3/4885MTNR1A 61/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR7 32/4885HTR2C 3/4885MTNR1A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.